Welcome to our dedicated page for Virpax Pharmaceuticals news (Ticker: VRPX), a resource for investors and traders seeking the latest updates and insights on Virpax Pharmaceuticals stock.
Virpax Pharmaceuticals (VRPX) is advancing non-opioid pain management through innovative drug delivery systems, including metered-dose sprays and liposomal formulations. This news hub provides investors and industry observers with timely updates on preclinical developments, regulatory milestones, and strategic partnerships.
Our curated collection of VRPX news offers essential insights into the company's progress in developing alternatives to traditional pain therapies. Track updates across key areas including product pipeline advancements, intellectual property developments, and global research collaborations that shape the future of pain treatment.
Discover official press releases detailing Virpax's work on enkephalin-based therapies and hydrogel encapsulation technologies. Stay informed about critical updates through verified financial disclosures and scientific progress reports, all maintained in one centralized location for efficient research.
Bookmark this page for ongoing access to VRPX's latest achievements in pharmaceutical innovation. Check regularly for new developments in their mission to enhance therapeutic outcomes while reducing opioid dependency risks.
Virpax Pharmaceuticals (NASDAQ: VRPX) has engaged Dr. Pardeep Gupta, an expert in liposomal drug delivery, to aid in the development of its patented long-acting injectable Probudur, designed for postoperative pain management. Dr. Gupta's role will focus on advising on chemistry, manufacturing, and controls, essential for the commercialization process. Probudur aims to provide pain relief for up to 96 hours, reducing dependency on opioids. This strategic hiring aligns with Virpax's goal of advancing its Investigational New Drug (IND) package for Probudur, with CEO Anthony P. Mack expressing optimism about Dr. Gupta’s contributions. Virpax is primarily focused on developing non-addictive pain management solutions using proprietary drug delivery technologies.
